| Literature DB >> 35566618 |
Katarzyna Zawadzka-Starczewska1, Bogusław Tymoniuk2, Bartłomiej Stasiak3, Andrzej Lewiński1,4, Magdalena Stasiak1.
Abstract
The association between HLA and the risk of Graves' disease (GD) has been analyzed for many years. However, the results were often inconsistent and mostly regarded Asian populations. The purpose of our study was to perform HLA genotyping using a next-generation sequencing (NGS) method in Caucasians, to find out which alleles are eventually correlated with GD morbidity as well as which of them can be considered protective. HLA-A, -B, -C, -DQB1, -DRB1 were genotyped using a next-generation sequencing method in 2376 persons, including 159 GD patients and 2217 healthy controls. We have demonstrated a significant association between the risk of GD and the following alleles: HLA-B*08:01, -B*39:06, -B*37:01, -C*07:01, -C*14:02, -C*03:02, -C*17:01, -DRB1*03:01, -DRB1*11:01, -DRB1*13:03, -DRB1*01:03, -DRB1*14:01, -DQB1*03:01, DQB1*02:01. The alleles HLA-B*39:06, -B*37:01, -C*14:02, -C*03:02, -C*17:01, -DRB1*14:01 are novel GD-associated, previously not-reported independent ones with no linkage disequilibrium with other high-risk alleles. On the other hand, the frequencies of HLA-B*07:02, -C*07:02, -C*03:04, DRB1*07:01, -DQB1*02:02, -DQB1*03:03 were significantly lower in GD compared to controls. This study demonstrated the actual relationships between HLA and GD based on the NGS method and provided a novel set of alleles as a reliable tool for an individual personalized risk assessment.Entities:
Keywords: Graves’ disease; HLA; human leukocyte antigen; susceptibility alleles
Year: 2022 PMID: 35566618 PMCID: PMC9099647 DOI: 10.3390/jcm11092492
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Laboratory characteristics of the Graves’ disease (GD) group.
| Parameter (Reference Range and Units) | Mean ± SD | Median |
|---|---|---|
| TSH (0.27–4.2 µIU/mL) | 0.14 ± 0.43 | 0.05 |
| FT4 (0.9–1.7 ng/dL) | 3.35 ± 2.39 | 2.33 |
| FT3 (2.0–4.4 pg/mL) | 11.07 ± 8.38 | 7.86 |
| TRAb (<1.7 IU/L) | 15.04 ± 13.62 | 10.12 |
Abbreviations: FT3, free triiodothyronine; FT4, free thyroxine; SD, standard deviation; TRAb, TSH receptor antibodies; TSH, thyrotropin.
Figure 1Frequencies (%) of human leukocyte antigen (HLA) over-represented alleles with statistically significant difference between control (open bars) and Graves’ disease (GD) patients (solid bars) for major histocompatibility complex (MHC) class I alleles: HLA-B (a) and HLA-C (b).
Figure 2Frequencies (%) of human leukocyte antigen (HLA_ over-represented alleles with statistically significant difference between control (open bars) and Graves’ disease (GD) patients (solid bars) for major histocompatibility complex (MHC) class II alleles: HLA-DRB1 (a) and HLA-DQB1 (b).
Figure 3Frequencies (%) of human leukocyte antigen (HLA) under-represented alleles with statistical difference between controls (open bars) and Graves’ disease (GD) patients (solid bars) for both major histocompatibility complex (MHC) class I and class II alleles.
Frequencies and linkage disequilibrium of three-locus HLA-B-DRB1-DQB1 haplotypes in Graves’ disease (GD) patients depending on the presence of the HLA-B*08:01 allele.
| HLA Haplotype | Haplotype Frequency |
|---|---|
|
| 22% [ |
|
| 6.6% [ |
|
| 1.9% [ |
B*XX:XX—allele other than -B*08:01; DRB1*XX:XX- DQB1*XX:XX—alleles other than -DRB1*03:01,- DQB1*02:01.